share_log

基石藥業-B：自願公告 - 首席執行官兼執行董事楊建新博士新增購買公司334.5萬股股份，累計購買752.95萬股股份

CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - FURTHER INCREASE IN SHAREHOLDING BY CEO AND EXECUTIVE DIRECTOR DR. JIANXIN YANG BY 3,345,000 SHARES, WITH ACCUMULATED PURCHASE TOTALLING 7,529,500 SHARES

Hong Kong Stock Exchange ·  Apr 29 12:00
Summary by Futu AI
基石藥業-B（「本公司」）首席執行官兼執行董事楊建新博士於近六個月內以自有資金在公開市場上購買公司股份共3,345,000股，並於2022年8月至今累計增持至7,529,500股，持股比例達到公司已發行股本總額的約4.97%。楊博士表示，此舉反映了他對公司未來前景的信心及對公司穩健經營和快速增長能力的信任。董事會認為，楊博士的增持行為體現了對公司的長期承諾及對未來業務前景的樂觀。基石藥業專注於創新腫瘤免疫治療及精准治療藥物的研發和商業化，旨在滿足中國大陸和全球癌症患者的需求，並已建立了包含12種腫瘤候選藥物的產品管線。
基石藥業-B（「本公司」）首席執行官兼執行董事楊建新博士於近六個月內以自有資金在公開市場上購買公司股份共3,345,000股，並於2022年8月至今累計增持至7,529,500股，持股比例達到公司已發行股本總額的約4.97%。楊博士表示，此舉反映了他對公司未來前景的信心及對公司穩健經營和快速增長能力的信任。董事會認為，楊博士的增持行為體現了對公司的長期承諾及對未來業務前景的樂觀。基石藥業專注於創新腫瘤免疫治療及精准治療藥物的研發和商業化，旨在滿足中國大陸和全球癌症患者的需求，並已建立了包含12種腫瘤候選藥物的產品管線。
Dr. Yang Jianxin, CEO and Executive Director of Keystone Pharmaceutical-B (the “Company”), purchased 3,345,000 shares of the Company on the public market with own funds in the last six months, increasing the total to 7,529,500 shares in August 2022, reaching approximately 4.97% of the Company's total issued share capital in August 2022.。 Dr. Yang said the move reflects his confidence in the company's future prospects and confidence in the company's sound business and ability to grow rapidly. The Board believes that Dr. Yang's growth reflects his long-term commitment to the Company and his optimism for future business prospects. KEYSTONE PHARMACEUTICALS FOCUSES ON THE R&D AND COMMERCIALIZATION OF INNOVATIVE TUMOR IMMUNOTHERAPY AND PRECISION THERAPY DRUGS TO MEET THE NEEDS OF CANCER PATIENTS IN MAINLAND CHINA AND GLOBALLY, AND HAS ESTABLISHED A PRODUCT PIPELINE THAT INCLUDES 12 TUMOR CANDIDATE DRUGS.
Dr. Yang Jianxin, CEO and Executive Director of Keystone Pharmaceutical-B (the “Company”), purchased 3,345,000 shares of the Company on the public market with own funds in the last six months, increasing the total to 7,529,500 shares in August 2022, reaching approximately 4.97% of the Company's total issued share capital in August 2022.。 Dr. Yang said the move reflects his confidence in the company's future prospects and confidence in the company's sound business and ability to grow rapidly. The Board believes that Dr. Yang's growth reflects his long-term commitment to the Company and his optimism for future business prospects. KEYSTONE PHARMACEUTICALS FOCUSES ON THE R&D AND COMMERCIALIZATION OF INNOVATIVE TUMOR IMMUNOTHERAPY AND PRECISION THERAPY DRUGS TO MEET THE NEEDS OF CANCER PATIENTS IN MAINLAND CHINA AND GLOBALLY, AND HAS ESTABLISHED A PRODUCT PIPELINE THAT INCLUDES 12 TUMOR CANDIDATE DRUGS.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.